SA516380194B1 - ارتباط جسم مضاد بـ FcRn لعلاج أمراض مناعة ذاتية - Google Patents

ارتباط جسم مضاد بـ FcRn لعلاج أمراض مناعة ذاتية Download PDF

Info

Publication number
SA516380194B1
SA516380194B1 SA516380194A SA516380194A SA516380194B1 SA 516380194 B1 SA516380194 B1 SA 516380194B1 SA 516380194 A SA516380194 A SA 516380194A SA 516380194 A SA516380194 A SA 516380194A SA 516380194 B1 SA516380194 B1 SA 516380194B1
Authority
SA
Saudi Arabia
Prior art keywords
antibody
amino acid
acid sequence
antigen
antibodies
Prior art date
Application number
SA516380194A
Other languages
Arabic (ar)
English (en)
Inventor
كيم سون إيون
هيونج يو تاي
كاب جونج جاي
شين دونجوك
كوك بارك سونغ
ووك كيم سونغ
سون كيم مين
كيونغ اهن هاي
يونغ هاي-يونغ
جونغ سونج يونغ
Original Assignee
هانال بيوفارما كو.,ليمتد.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by هانال بيوفارما كو.,ليمتد. filed Critical هانال بيوفارما كو.,ليمتد.
Publication of SA516380194B1 publication Critical patent/SA516380194B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rehabilitation Therapy (AREA)
SA516380194A 2014-04-30 2016-10-30 ارتباط جسم مضاد بـ FcRn لعلاج أمراض مناعة ذاتية SA516380194B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461986742P 2014-04-30 2014-04-30
PCT/KR2015/004424 WO2015167293A1 (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases

Publications (1)

Publication Number Publication Date
SA516380194B1 true SA516380194B1 (ar) 2020-10-14

Family

ID=54358928

Family Applications (1)

Application Number Title Priority Date Filing Date
SA516380194A SA516380194B1 (ar) 2014-04-30 2016-10-30 ارتباط جسم مضاد بـ FcRn لعلاج أمراض مناعة ذاتية

Country Status (21)

Country Link
US (6) US10544226B2 (2)
EP (2) EP3137504B1 (2)
JP (1) JP6449441B2 (2)
KR (2) KR101954906B1 (2)
CN (2) CN106459215B (2)
AU (2) AU2015253915B2 (2)
CA (2) CA2945086C (2)
DK (1) DK3137504T5 (2)
EA (1) EA038470B1 (2)
ES (1) ES2952583T3 (2)
FI (1) FI3137504T3 (2)
HU (1) HUE062403T2 (2)
IL (2) IL248159B (2)
MX (2) MX382284B (2)
NZ (2) NZ726089A (2)
PL (1) PL3137504T3 (2)
PT (1) PT3137504T (2)
RS (1) RS64542B1 (2)
SA (1) SA516380194B1 (2)
SG (1) SG11201608208VA (2)
WO (1) WO2015167293A1 (2)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106957365B (zh) 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
ES2864211T3 (es) * 2016-04-25 2021-10-13 Syntimmune Inc Anticuerpos anti-FcRn humanizados con maduración de la afinidad
CA3032415A1 (en) * 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
SG11201911832PA (en) * 2017-06-15 2020-01-30 UCB Biopharma SRL Method for the treatment of immune thrombocytopenia
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
KR102921210B1 (ko) 2018-07-20 2026-01-30 모멘타 파머슈티컬스 인코포레이티드 Fcrn 항체 조성물
MA53903A (fr) 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
US20220002402A1 (en) * 2018-11-06 2022-01-06 Immunovant Sciences Gmbh Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
US20230049011A1 (en) 2019-11-19 2023-02-16 Immunovant Sciences Gmbh Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
CN114341184B (zh) * 2020-02-10 2023-04-04 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
KR20220001482A (ko) * 2020-06-29 2022-01-05 한올바이오파마주식회사 항-FcRn 항체에 대한 제형
CN116490208A (zh) * 2020-08-06 2023-07-25 史坦利科西斯治疗有限责任公司 Il-8抗体及其使用方法
CN113484526B (zh) * 2021-08-11 2024-08-23 上海迈晋生物医药科技有限公司 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法
US20250136699A1 (en) * 2021-08-13 2025-05-01 Jiangsu Biojetay Biotechnology Co., Ltd. Antibodies specifically recognizing fcrn and uses thereof
US20250026814A1 (en) * 2021-11-16 2025-01-23 The University Of Chicago Polypeptides for detection and treatment of coronavirus infection
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
AU2023281650A1 (en) * 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
TW202409085A (zh) 2022-05-30 2024-03-01 南韓商韓兀生物製藥股份有限公司 具有改善之安定性的抗ＦｃＲｎ抗體或其抗原結合片段
MA71603A (fr) * 2022-07-27 2025-05-30 Ablynx Nv Polypeptides se liant à un épitope spécifique du récepteur fc néonatal
WO2024052358A1 (en) 2022-09-06 2024-03-14 Immunovant Sciences Gmbh Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies
US20260078188A1 (en) 2022-09-06 2026-03-19 Immunovant Sciences Gmbh Methods of treating graves’ disease using anti-fcrn antibodies
EP4676963A1 (en) 2023-03-08 2026-01-14 Immunovant Sciences GmbH High concentration protein formulations with polysorbate excipients and methods of making the same
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
CN121843716A (zh) 2023-07-16 2026-04-10 阿根思有限公司 用于治疗慢性炎性脱髓鞘性多发性神经病的方法
WO2025093717A1 (en) * 2023-10-31 2025-05-08 Immunovant Sciences Gmbh Methods of improving anti-fcrn therapies
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
CN119490588B (zh) * 2024-10-17 2026-03-06 广州康盛生物科技股份有限公司 一种抗人FcRn的VHH抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
JP2007501847A (ja) 2003-08-08 2007-02-01 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CA2606378A1 (en) * 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
JP2009524664A (ja) 2006-01-25 2009-07-02 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／アロ免疫疾患の治療のための抗−ｆｃｒｎ抗体
DK2602323T3 (en) 2007-06-01 2018-04-16 Open Monoclonal Tech Inc Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies
BRPI0910622A2 (pt) * 2008-04-25 2020-03-10 Dyax Corp. ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
KR102014554B1 (ko) * 2011-06-02 2019-08-26 다이액스 코포레이션 Fc 수용체 결합 단백질
KR20130071961A (ko) * 2011-12-21 2013-07-01 한올바이오파마주식회사 ＦｃＲｎ 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
KR20210094669A (ko) 2013-04-29 2021-07-29 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물

Also Published As

Publication number Publication date
HUE062403T2 (hu) 2023-10-28
US20190135917A1 (en) 2019-05-09
PL3137504T3 (pl) 2023-10-16
KR20180093128A (ko) 2018-08-20
RS64542B1 (sr) 2023-09-29
JP2017522043A (ja) 2017-08-10
CN111138540A (zh) 2020-05-12
SG11201608208VA (en) 2016-11-29
DK3137504T5 (en) 2024-10-14
MX2021005193A (es) 2021-09-08
KR20160145779A (ko) 2016-12-20
CA2945086A1 (en) 2015-11-05
EP4241852A2 (en) 2023-09-13
NZ726089A (en) 2017-12-22
KR101889466B1 (ko) 2018-08-21
PT3137504T (pt) 2023-08-18
AU2015253915B2 (en) 2018-05-10
US20240092913A1 (en) 2024-03-21
MX382284B (es) 2025-03-13
FI3137504T3 (fi) 2023-08-07
DK3137504T3 (da) 2023-08-14
IL248159A0 (en) 2016-11-30
CA3095295A1 (en) 2015-11-05
EP3137504A4 (en) 2018-02-28
EP4241852A3 (en) 2023-11-15
CA3095295C (en) 2023-01-10
AU2018203582B2 (en) 2019-05-02
US20170210801A1 (en) 2017-07-27
US20200109201A1 (en) 2020-04-09
CA2945086C (en) 2020-12-29
EP3137504B1 (en) 2023-05-10
IL248159B (en) 2021-02-28
US10544226B2 (en) 2020-01-28
IL280613A (en) 2021-03-25
AU2015253915A1 (en) 2016-12-01
NZ737666A (en) 2018-10-26
ES2952583T3 (es) 2023-11-02
KR101954906B1 (ko) 2019-03-08
MX2016014210A (es) 2017-05-01
AU2018203582A1 (en) 2018-06-14
CN106459215A (zh) 2017-02-22
CN111138540B (zh) 2023-07-25
US11613578B2 (en) 2023-03-28
EA038470B1 (ru) 2021-09-01
US20250026835A1 (en) 2025-01-23
US20230235063A1 (en) 2023-07-27
IL280613B (en) 2021-12-01
JP6449441B2 (ja) 2019-01-09
WO2015167293A1 (en) 2015-11-05
EA201692192A1 (ru) 2017-04-28
BR112016025319A2 (pt) 2017-12-12
CN106459215B (zh) 2019-12-24
EP3137504A1 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
SA516380194B1 (ar) ارتباط جسم مضاد بـ FcRn لعلاج أمراض مناعة ذاتية
US10280207B2 (en) FcRn-specific human antibody and composition for treatment of autoimmune diseases
SA519401906B1 (ar) أجسام مضادة ومتعددات ببتيد موجهة ضد cd127
US10336825B2 (en) Antibody binding to FcRn for treating autoimmune diseases
SA516371109B1 (ar) 1a أجسام مضادة خاصة لمركب ترابطي يشبه عامل تنكرز ورم وتركيباتها واستخدامها
EP3229829B1 (en) Method for the treatment of idiopathic pulmonary fibrosis
DK1960432T3 (en) Anti-ICAM-antistof der inducerer apoptose
US8828387B2 (en) Antibody having anti-cancer activity
US12435135B2 (en) Human CD47-targeting single-domain antibody and use thereof
KR20220100880A (ko) 항-fcrn 항체를 이용한 온열 자가면역 용혈성 빈혈 치료 방법
CN116323657B (zh) 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
WO2022068894A1 (zh) 同时靶向pd-l1和vegf的双功能分子及其医药用途
CN119192371A (zh) 抗s100a8/a9抗体及其用途
TWI623324B (zh) 用於治療自體免疫病的與fcrn結合的抗體
JP2024520635A (ja) 抗体及びそれを生成する方法
HK1230217A1 (en) Antibody binding to fcrn for treating autoimmune diseases
HK40018330A (en) Antibody binding to fcrn for treating autoimmune diseases
HK40018330B (zh) 治疗自身免疫疾病的结合fcrn的抗体
BR112016025319B1 (pt) Anticorpo anti-fcrn isolado, polinucleotídeos, vetor de expressão recombinante, composições e método para detectar fcrn in vitro
HK1230217B (zh) 治疗自身免疫疾病的结合fcrn的抗体